Clinical association of autoantibodies to fibrillarin with diffuse scleroderma and disseminated telangiectasia

Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis

“…A previous study by Okano et a1 (14), however, failed to detect antifibrillarin in a large number of SSc sera not showing nucleolar staining of HEp-2 cells. Moreover, the overall frequency of antifibrillarin (8%) in this series of SSc patients is comparable with that found in several other studies (5,14,17,18).…”

Comparative qualitative and quantitative analysis of scleroderma (systemic sclerosis) serologic immunoassays

“…The latter might explain the absence of U 3 RNA in 4 out of 7 anti-fibrillarin positive sera tested with immunoprecipitation using radiolabelled extract in the present study, but the small number of samples does not contribute to an explanation. Like previously reported findings [68], anti-fibrillarin antibodies were detected with higher frequency in patients with dSSc (22%) than in those with lSSc (6%), but the small amount of positive sera detected, does not permit statistically significant clinical correlations. Antifibrillarin antibodies coexisted with anti-Topo I antibodies in 10 patients (13%), the majority corresponding to the dSSc disease subset, which represents a rather high frequency, since other investigators suggest a rare coexistence of these specificities [69].…”

Autoantibody to U3 Nucleolar Ribonucleoprotein (Fibrillarin) In Patients with Systemic Sclerosis

“…Recently, Kurzhals et al described 3 patients with antifibrillarin antibodies who had diffuse cutaneous involvement and widespread telangiectasia (12). Kuhn et a1 also described 3 patients with antifibrillarin antibodies and diffuse cutaneous involvement (13).…”